Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;135(6):981-9.
doi: 10.1542/peds.2014-3358. Epub 2015 May 4.

Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic

Anna M Acosta  1 , Chas DeBolt  2 , Azadeh Tasslimi  2 , Melissa Lewis  3 , Laurie K Stewart  2 , Lara K Misegades  4 , Nancy E Messonnier  4 , Thomas A Clark  4 , Stacey W Martin  4 , Manisha Patel  4
Affiliations

Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic

Anna M Acosta et al. Pediatrics. 2015 Jun.

Abstract

Background: Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents who have received all acellular vaccines are limited.

Methods: To assess Tdap VE and duration of protection, we conducted a matched case-control study during the 2012 pertussis epidemic in Washington among adolescents born during 1993-2000. All pertussis cases reported from January 1 through June 30, 2012, in 7 counties were included; 3 controls were matched by primary provider clinic and birth year to each case. Vaccination histories were obtained through medical records, the state immunization registry, and parent interviews. Participants were classified by type of pertussis vaccine received on the basis of birth year: a mix of whole-cell and acellular vaccines (1993-1997) or all acellular vaccines (1998-2000). We used conditional logistic regression to calculate odds ratios comparing Tdap receipt between cases and controls.

Results: Among adolescents who received all acellular vaccines (450 cases, 1246 controls), overall Tdap VE was 63.9% (95% confidence interval [CI]: 50% to 74%). VE within 1 year of vaccination was 73% (95% CI: 60% to 82%). At 2 to 4 years postvaccination, VE declined to 34% (95% CI: -0.03% to 58%).

Conclusions: Tdap protection wanes within 2 to 4 years. Lack of long-term protection after vaccination is likely contributing to increases in pertussis among adolescents.

Keywords: adolescent; diphtheria-tetanus-acellular pertussis vaccine; diphtheria-tetanus-pertussis vaccine; whooping cough.

PubMed Disclaimer

Conflict of interest statement

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Estimated Tdap duration of protection against pertussis among adolescents who received all acellular vaccines (birth years 1998–2000), restricted to confirmed cases or participants with complete and on-schedule childhood series. Acellular vaccine group: adolescents born from 1998 to 2000, assumed to have received all acellular pertussis vaccines for the childhood series (cases = 450, controls = 1256). Acellular vaccine group, confirmed case status: adolescents born from 1998 to 2000, assumed to have received all acellular pertussis vaccines for the childhood series and restricted to confirmed cases and their associated controls (cases = 355, controls = 984). Acellular vaccine group, complete and on-schedule childhood series: adolescents born from 1998 to 2000, assumed to have received all acellular pertussis vaccines for the childhood series and restricted to cases and controls with 5 childhood doses on schedule (cases = 288, controls = 728). A complete and on-schedule primary series is considered the following: doses 1 through 3 before the first birthday, dose 4 on or after the first birthday and before the second birthday, and dose 5 on or after the fourth birthday and before the seventh birthday. Refer to Table 3 and Supplemental Tables 5 and 6 for CIs for each of these time points.
FIGURE 2
FIGURE 2
Time since Tdap vaccination, by vaccine group. Acellular vaccine group: adolescents born from 1998 to 2000, assumed to have received all acellular pertussis vaccines for the childhood series (cases = 450, controls = 1256). Mixed-vaccine group: adolescents born from 1993 to 1997, assumed to have received a mix of whole-cell and acellular pertussis vaccines (cases = 386, controls = 1076).
See this image and copyright information in PMC

Comment in

References

    1. Division of Integrated Surveillance Systems and Services, National Center for Public Health Informatics, Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention, US Department of Health and Human Services. [Accessed August 12, 2013];National Notifiable Disease Surveillance System. Available at: www.cdc.gov/pertussis/surv-reporting.html.
    1. Centers for Disease Control and Prevention. Pertussis epidemic—Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61(28):517–522. - PubMed
    1. Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr. 2012;161(6):1091–1096. - PubMed
    1. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308(20):2126–2132. - PubMed
    1. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012–1019. - PubMed

Publication types

Substances